No Data
No Data
Kronos Bio To Present Data At ACR Convergence 2024 To Support P300 KAT Inhibition As An Approach To Anti-Inflammatory Therapy
Guggenheim Initiates Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $96
Keros Therapeutics Is Maintained at Buy by B of A Securities
Keros Therapeutics Analyst Ratings
BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $76
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Harmony Biosciences Holdings (HRMY) and Keros Therapeutics (KROS)
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long